natgillin/translations-raw huggingface dataset:
The compound according to any one of claims 1 to 6 or the composition according to claim 7, for use in the treatment of obesity in a mammal, preferably a human being. 
Tvar u skladu s bilo kojim od patentnih zahtjeva 1 do 6 ili sastav u skladu s patentnim zahtjevom 7, za uporabu u liječenju pretilosti kod sisavaca, poželjno kod ljudskih bića.
Suitably, the compounds of Formula (I) are useful for the treatment of autoimmune diseases or inflammatory diseases such as multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosis, inflammatory bowel disease, lung inflammation, thrombosis or brain infection/inflammation such as meningitis or encephalitis. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se bolesno stanje bira iz skupine koju čine: multipla skleroza, psorijaza, reumatoidni artritis, sistemni eritematozni lupus, upalna bolest crijeva, upala pluća, tromboza, infekcija/fupala mozga, meningitis i encefalitis.
These and other data show that a MW corresponding to monomeric IL-2 is seen above about 600µg/mg, and MW starts to increase significantly when SDS is below about 300µg/mg, with the increase becoming very steep when SDS drops below about 100µg/mg. 
Ovi i drugi podaci pokazuju da se MW koji odgovara monomernom IL-2 vidi iznad oko 600ug/mg, a MW počinje da značajno raste kada je SDS ispod oko 300ug/mg, s povećanjem koje postaje vrlo strmo kada SDS pada ispod oko 100ug/mg.
The compound or salt of claim 14 for use wherein said skin disorder is psoriasis. 
Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj esencijalna trombocitemija (ET).
The chimeric molecule of claim 9, wherein the ligand is an antibody or fragment thereof which has antigen recognition capability. 
Kimerička molekula iz zahtjeva 6, nadalje naznačena time da je (a) neko njeno antitijelo ili fragment antitijela koji zadržava sposobnost prepoznavanja antigena.
See text for more details. Method of detecting Pneumocandin B0 and/or Pneumocandin C0 in a sample, wherein Pneumocandin B0 specific fragment and/or Pneumocandin C0 specific fragment is/are detected using tandem Mass Spectrometry in negative mode. 
Postupak za detekciju Pneumokandina B, i/ili Pneumokandina Co u uzorku, naznačen time da se specifični fragment Pneumokandina Bo i/ili specifični fragment Pneumokandina Cy detektira korištenjem tandem masene spektrometrije u negativnom načinu rada.
The method of claim 1, wherein the method is validated for use in multiple sclerosis (MS) and Crohn's Disease (CD) patients. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što subjekt ima multiplu sklerozu (MS) ili Crohnovu bolest (CD).
US 3,841,555 discloses a spray apparatus using pressurized air. 
US 3,841,555 opisuje uređaj za raspršivanje u obliku spreja koji koristi zrak pod tlakom.
of Formula (I) is the following formula: 
Formule (1) jest slijedeća formula:
wherein the fatty acid is a straight, branched, saturated or unsaturated fatty acid with a chain length of 4 to 20 carbon atoms. 
HR P2071947 TI kiselina nerazgranata, razgranata, zasićena ili nezasićena masna kiselina s duljinom lanca od 4 do 20 atoma ugljika.
At least for a fraction of the socket forming time the process air, maintained at the socket forming pressure, presses the end 20 of the pipe 2 onto the outer lateral walls 130 of the forming mandrel 13 . 
- <- barem tijekom dijela vremena formiranja čahure zrak za postupak, koji se održava na pritisku za formiranje čahure, pritišće završetak (20) cijevi (2) prema vanjskim bočnim stjenkama (130) roga za oblikovanje (13).
The TGFB antagonist for use according to Claim 1, wherein said TGFB antagonist is an agent that blocks the binding of a TGFB protein to its receptor. 
Antagonist TGFB za uporabu u skladu sa zahtjevom 1, naznačen time što je navedeni antagonist TGFB sredstvo koje blokira vezanje TGFB proteina na njegov receptor.
The composition of para 1 wherein R3 is selected from ethylenediamine and cyclohexanediamine. 
Pripravak za uporabu u postupku liječenja raka prema zahtjevu 1 naznačen time da je R* odabran od etilendiamina i cikloheksandiamina.
The method according to claim 1, wherein the average oil droplet size of the emulsion prepared in step (i) is 5000 nm or less. 
Postupak prema zahtjevu 1, naznačen time da je prva prosječna veličina uljne kapljice 5000 nm ili manje.
An inhalation device suitable for delivery of the medicament in dry powder form from a blister package composed of a plurality of blister pockets which are spaced at equal intervals, each of which comprises medicament in dry powder form; the inhalation device comprising: 
HR P20160515 T1 PATENTNI ZAHTJEVI 1. Uređaj za inhaliranje koji je pogodan za dostavu lijeka u suhom praškastom obliku iz blister pakiranja koje je sastavljeno od većeg broja blister džepova razmaknutih u jednakim intervalima, svaki od kojih sadrži lijek u suhom praškastom obliku; te uređaj za inhaliranje sadrži:
The pharmaceutical composition according to claim 3, wherein the pharmaceutical composition comprises about 0.5 mg to about 1000 mg of the crystalline form of 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 7-9, naznačen time da navedeni farmaceutski pripravak sadrži od 0.5 mg do 1000 mg kristalnog 4-[7-(6-cijano-5-trifluorometilpiridin-3-11)-8-okso-6-tiokso-5,7-diazaspiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamida.
Functional derivatives of IL-18BP may be conjugated to polymers in order to improve the properties of the protein, such as the stability, half-life, bioavailability, tolerance by the human body, or immunogenicity. 
Funkcionalni derivati IL-18BP mogu biti konjugirani za polimere kako bi se poboljšale karakteristike proteina poput stabilnosti, polu života, biodostupnosti, tolerancije u ljudskom tijelu ili imunogenosti.
The method of claim 2 wherein the therapeutically effective amount of the compound of claim 1 is from about 1 mg/dose to about 100 mg/dose. 
Spoj za uporabu kako je zatraženo u zahtjevu 30 naznačen time da terapeutski učinkovita količina spoja prema zahtjevu 1 je od oko 1 mg/dozi do oko 100 mg/dozi.
The method of any preceding claim, wherein classifying the plurality of polymorphism comprises applying a threshold to the allele frequency determined in (e). 
pri čemu razvrstavanje najmanje jednog naznačenog polimorfizma obuhvaća primjenu praga na učestalost alela određenu u (d);
The aerosol produced by the preferred articles of the present invention is chemically simple, consisting essentially of air, oxides of carbon, the aerosol which carries any desired flavorants or other desired volatile materials, water, and trace amounts of other materials. 
Aerosgol koji je proizveden poželjnim proizvodima iz sadašnjeg izuma je kemijski prost i sastoji se bitno od zraka, oksida ugljika, aerosola koji nosi željena mirisna sredstva, ili druge željene isparljive materijale, vode 1 količine drugih materijala u tragovima.
in tetrahydrofuran and potassium carbonate at a temperature in the range of −10° C. to 0° C. for a period of 4.5 hours to 5.5 hours to obtain 2-chloro-N-[4-(1-cyclobutyl piperidin-4-yloxy) phenyl] acetamide of formula (8) and recrystallizing the compound of formula (8) using isopropanol and methanol under reflux for a period of 0.5 to 1 hour; 
NH, DA 6 7) u tetrahidrofuranu i kalij karbonatu na temperaturi u rasponu od -10 *C do 0 *C u trajanju od 4,5 sati do 5,5 sati da se dobije 2-kloro-N-[4-(1-ciklobutil piperidin-4-iloksi) fenil] acetamid iz formule (8) i rekristalizacija spoja iz formule (8) uporabom izopropanola i metanola pod refluksom u trajanju od 0,5 do 1 sat;
The method according to claim 11 wherein the derivatised sample is subjected to a recrystallisation step prior to the sample being analysed by MALDI-TOF. 
Metoda prema patentnom zahtjevu 11 gdje derivatizirani uzorak je podvrgnut koraku rekristalizacije prije nego što je uzorak analiziran pomoću MALDI-TOF.
purifying the immunoglobulin with one or more chromatography steps, and providing an immunoglobulin solution, 
pročišćivanje imunoglobulina kroz jednu ili više kromatografskih faza, te pripremanje otopine imunoglobulina;
G is a direct bond; 
G je direktna veza;
The compound for use of any of claims 1-10, wherein the cancer is rectal adenocarcinoma, unresectable colorectal carcinoma, metastatic hepatocellular carcinoma, peritoneal carcinoma, papillary serous carcinoma, unresectable hepatocellular carcinoma, papillary thyroid carcinoma, follicular thyroid carcinoma or medullary thyroid carcinoma. 
Tvar za uporabu iz bilo kojeg od patentnih zahtjeva 1-10, pri čemu je rak rektalni adenokarcinom, neoperabilni kolorektalni karcinom, metastatski hepatocelularni karcinom, peritonealni karcinom, papilarni serozni karcinom, nesekretabilni hepatocelularni karcinom, papilarni tiroidni karcinom, folikularni tiroidni karcinom ili medularni tiroidni karcinom.
reaction (O1-reac) is a reaction of compound of formula (XXIII) with water and with a compound (O1-comp); 
Pri tome se kod reakcije (N-reak.) radi o reakciji spoja formule (XXII) sa katalizatorom (N-kat.);
The compound for use according to any one of claims 1 to 5, wherein the eye disease is diabetic retinopathy. 
Spoj za uporabu prema zahtjevu 5 ili 7, naznačen time što je bolest oka dijabetska retinopatija.
introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding a protein or at least one part thereof; wherein said host cell is selected to produce a protein composition having at least one of the following glycosylation characteristics: 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen proizvodnji pripravka s molekulom proteina, po mogućnosti pripravka s molekulom protutijela, gdje se navedenu stanicu domaćin tako bira da proizvodi pripravak s proteinom koji ima najmanje jednu od sljedećih značajki glikoziliranja:
Matrix metalloproteinase inhibitors This invention relates to novel chemical compounds, processes for their preparation, pharmaceutical formulations containing them and their use in therapy. 
Ovaj izum odnosi se na nove kemijske spojeve, na postupke njihovog dobivanja, na farmaceutske formulacije koje ih sadrže, te na njihovu upotrebu u terapiji.
The pharmaceutical composition according to claim 17 for treating or diagnosing a VAP-1 mediated inflammatory disorder selected from the group consisting of arthritides and connective tissue diseases, inflammatory bowel diseases, dermatoses, multiple sclerosis, inflammatory neuropathy, inflammatory myopathy, acute disseminated encephalomyelitis, vasculitis of the central nervous system, Sjögrens syndrome, diabetes, systemic lupus erythematosus, asthma, inflammatory liver disease, Graves disease and thyroiditis. 
Farmaceutski pripravak prema zahtjevu 17 za uporabu u liječenju ili dijagnostici VAP-1 posredovanog upalnog poremećaja izabranog iz skupine koja se sastoji od artritisa i bolesti vezivnog tkiva, upalnih bolesti crijeva, dermatoze, multiple skleroze, upalne neuropatije, upalne miopatije, akutnog diseminiranog encefalomijelitisa, vaskulitisa središnjeg živčanog sustava, Sjčgrenovog sindroma, dijabetesa, sustavnog eritemskog lupusa, astme, upalne bolesti jetre, Gravesove bolesti i tiroiditisa.
Said compositions contain the active ingredient in admixture with a carrier, such as sugar, gum Arabic, tragacanth gum, gelatine, glycerol or the like. 
Navedeni sastavi sadrže aktivnu tvar u smjesi sa nosačem, poput šećera, gume arabice, tragakanta, želatine, glicerola ili slično.
The method according to claim 1, wherein R3 is a C1 to C6 alkyl group, a benzyl group, or an indolylmethyl group, the indolyl group optionally being substituted at the nitrogen atom thereof by a C1 to C6 alkyl group. 
Spoj ili sol prema bilo kojem od zahtjeva 1 do 4, naznačen time, da je R* C1 do C6 alkilna skupina, benzilna skupina, ili indolilmetilna skupina (indolilna skupina po izboru je supstituirana na dušikovom atomu s C1 do C6 alkilnom skupinom).
The method as in claim 1, the method further comprising a step before the feeding step, the further step comprising mixing the solid thermoplastic particulates and the major portion of the viscous material to give the predispersion. 
Postupak prema zahtjevu 1, naznačen time, da nadalje sadrži korak prije koraka dodavanja, a dodatni korak uključuje miješanje čvrstih termoplastičnih čestica 1 glavninu viskoznog materijala, čime se dobije pre-disperzija.
Host cell of claim 9, whereby the higher eukaryotic host cell is a mammalian cell. 
Stanica domaćin prema zahtjevu 9, naznačena time da viša eukariotska stanica domaćin je stanica sisavca.
The cyclic peptide or the pharmaceutical composition of claim 26, wherein said heart disease is selected from the group consisting of infectious and non-infectious heart disease, ischemic and non-ischemic heart disease, inflammatory heart disease and myocarditis, cardiac dilatation, idiopathic cardio-myopathy, (idiopathic) dilated cardiomyopathy (DCM), immune-cardiomyopathy, heart failure, and any cardiac arrhythmia including ventricular and/or supraventricular premature capture beats as well as any atrial arrhythmia including atrial fibrillation and/or atrial flutter. 
Ciklički peptid, ili farmaceutski pripravak u skladu s patentnim zahtjevom 22, naznačen time što se navedenu srčanu bolest bira iz skupine koju čine infektivna i neinfektivna srčana bolest, ishemična i neishemična srčana bolest, upalna srčana bolest i miokarditis, proširenje srca, idiopatska kardiomiopatija, (idiopatska) dilatacijska kardiomiopatija (DCM), imunosna kardiomiopatija, srčana insuficijencija, te bilo koja srčana aritmija, uključujući ventrikularne i/ili supraventrikularne preuranjene (ekstrasistoličke) prihvatne otkucaje, kao i bilo koja atrijska aritmija, uključujući atrijsku fibrilaciju i/ili atrijsku undulaciju.
The compound according to claim 1 or 2 or a salt thereof, or a hydrate or a solvate thereof, wherein R2 is a C1-6 alkyl group substituted with 1 to 3 substituents selected from the substituent group 1. 
Spoj u skladu s patentnim zahtjevom 1 ili 2 ili sol istog ili hidrat ili solvat istog, naznačen time, da R2 je C1-6 alkilna skupina supstituirana s 1 do 3 supstituenta odabrana od supstituenta skupine 1.
a method for modulating a chemical or physical of interest of a co-crystal of any of claims 1-17, comprising: 
zahtjeva 1-7, naznačen time što se sastoji u: a) mjerenju kemijskog ili fizičkog svojstva od interesa spoja sa strukturom
Therefore, the treating method of the present invention allows preparation of an adipose extract, e.g. obtained by liposuction, which is in the form of a mixture of fluid materials and cell fragments and one or more cell macroagglomerates of heterogeneous sizes, in a cell suspension containing cell agglomerates, particularly adipocyte agglomerates, with smaller and identical or similar sizes, in any case, smaller than a given value, to allow transplantation into areas of the face or body of the patient, requiring a filling procedure with minor trauma, and accompanied by biological stimulation of the tissues involved in the procedure. 
PATENTNI ZAHTJEVI Metoda pripremanja adipoznog tkiva za transplantaciju, iz lobularne masti koja je izvučena, na primjer, pomoću liposukcije pri čemu se navedena mast sastoji od fluidne komponente koja sadrži uljanu komponentu, komponentu krvi i/ili sterilne otopine 1 od čvrste komponente koja sadrži fragmente stanica, stanice i jedan ili više staničnih makroaglomerata heterogene veličine, naznačena time da uključuje najmanje jedan korak ispiranja staničnih agregata koji je izveden u isto vrijeme kao 1 korak odvajanja fluidne komponente, u obliku emulzije, od čvrste komponente; navedeni korak ispiranja 1 odvajanja se odvija pomoću:
The composition according to claim 4 or 5, wherein the compounds are combined for a grouped or separate administration, simultaneously or sequentially. 
Smjesa prema zahtjevu 4 ili 5, gdje se spojevi kombiniraju za grupnu ili zasebnu primjenu, istodobno ili sekvencijski.
A pharmaceutical composition according to claim 1 or claim 2 wherein the second diluent which is practically insoluble in water and has ductile compression properties is microcrystalline cellulose. 
Farmaceutski pripravak u skladu sa zahtjevom I ili 2, naznačen time, da je drugo otapalo u osnovi netopivo u vodi iima svojstvo kompresijske rastezljivosti i predstavlja mikrokristalnu celulozu.
However, the composition may consist essentially of honey and L-alanyl-L-glutamine. 
Kompozicija u skladu sa prethodnim zahtjevima, koja se sastoji od meda i L-alanil-L-glutamina.
A well apparatus as claimed in claim 13, wherein the packer is provided on the casing string adjacent to a cemented-in portion of the casing. 
Bunarska aparatura, sukladno patentnim zahtjevima 10 ili 11, naznačeno time, da je paker osiguran na kućiš noj žici (12a,12b,12c,12d) pored zacementiranog dijela kućišta.
wherein: and R2 are as defined above, R3 is H or -COCH3; with the proviso that when Y is selected from the bivalent radicals mentioned under b)-f), the -ONO2 group is bound to -(CH2)n1; g) 
NHF" gdje ni, iR? jesu kao što su gore definirani, R? je Hili -COCH;, s ograničenjem da kada je Y odabran od dvovalentnih radikala spomenutih pod b)-f), -ONO, skupina je vezana za -(CH2),', 2
The method may comprise i) mixing the at least one active material and any excipients as dry material with a fluid to produce a paste; ii) forming the paste; iii) cutting the paste to a shape having at least one pointed end with an included angle of between about 10-50°; and iv) drying the paste. 
miješanje barem jednog aktivnog materijala i ekscipijenata kao suhog materijala sa fluidom da bi se proizvela ljekovita pasta; ii) < formiranje ljekovite paste; iii) "sečenje ljekovite paste na oblik koji ima barem jedan oštar kraj sa uglom koji obuhvata između oko 10- iv) sušenje ljekovite paste bilo prije ili posle koraka sečenja.
The compound of Claim 1 having Formula I": and pharmaceutically acceptable solvates thereof, wherein Ar1 is unsubstituted thiophen-2-yl, unsubstituted phenyl, or 4-fluorophenyl; 
[image] i njegovi farmaceutski prihvatljivi solvati, naznačen time da Ar1 je nesupstituirani tiofen-2-il, nesupstituirani fenil, ili 4-fluorofenil;
A beacon as claimed in claim 1, wherein adjacent said elongated printed circuits are connected mechanically and electrically by L-shaped arcs of conducting wire extending between adjacent end portions of said elongated printed circuits. 
Baliza prema patentnom zahtjevu 3, naznačena time, da su navedeni susjedni izduljeni štampani krugovi (52) povezani mehanički i električki L-oblikovanim lukovima (54) iz vodljive žice koja se proteže između susjednih krajnjih dijelova izduljenih štampanih krugova (52).
processing by assembling/ splicing (longitudinal, or crossfeed) 80 
obrada za slaganje/spajanje (uzdužno ili poprečno) 80
The reaction is concentrated in vacuo, and the resulting residue is dissolved in ethyl acetate. 
Reakcijsku smjesu koncentrira se u vakuumu, a dobiveni ostatak otopi u etilacetatu.
The pharmaceutical composition according to any one of claims 2 to 4, wherein the content of the hydrophobic substance is 0.5% by weight to 35% by weight with respect to the weight of the thickener. 
Farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time što je sadržaj hidrofobne tvari 0,5% težine do 35% težine u odnosu na težinu zgušnjivača.
An electrically heated smoking system according to claim 1, wherein the one or more electrically conductive tracks are on the outside of the tubular electrically insulating substrate. 
Električno grijani sustav za pušenje u skladu s patentnim zahtjevom 1, 2 1li 3, naznačen time što se jedna ili više električno vodljivih tračnica (203) nalazi s vanjske strane cijevi od električno izolirajuće podloge (201).
Use of an immunogenic composition comprising VZV gE antigen truncated to remove the carboxy terminal anchor region, wherein the gE truncate is not in the form of a fusion protein, and a TH-1 adjuvant comprising 3D-MPL, QS21 and liposomes comprising cholesterol in the preparation of a medicament for the prevention or amelioration of shingles and/or post herpetic neuralgia (i) in a population of individuals aged 50 or older or (ii) in a population of immunocompromised individuals. 
Imunogeni pripravak ili cjepivo, koji sadrže glikoprotein E kao antigen iz virusa varicela-zoster (VZV) (gE), skraćen kako bi se uklonilo C-terminalno sidrišno područje, gdje skraćeniVZV gE nije u obliku fuzijskog proteina, u kombinaciji s adjuvansom TH-1, koji sadrži QS21 i 3D MPL, naznačeni time što su namijenjeni upotrebi u sprječavanju ili ublažavanju zone i/ili postherpetične neuralgije.
V L The molecule of claim 19, wherein the peptide consists of an amino acid sequence shown in claim 21. 
Molekula prema zahtjevu 19, naznačena time, da se peptid sastoji od aminokiselinske sekvence prikazane u zahtjevu 21.
A compound of formula I: including its free form, salt form, stereoisomer, enantiomer, diastereomer, or hydrate, wherein Z is CH or N; 
HR P20140717 T1 PATENTNI ZAHTJEVI 1. Spoj formule I: lj uključujući njegov slobodni oblik, oblik soli, stereoizomer, enantiomer, dijastereomer ili hidrat, gdje
A pharmaceutical composition comprising the compound according to any one of Claims 1 to 3, and a pharmaceutically acceptable carrier, diluent or excipient in solution wherein the pH of said composition is less than 4.2 and greater than 2.0. 
Farmaceutski pripravak, naznačen time što sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 3,1 farmaceutski prihvatljiv nosač, razrjeđivač ili ekscipient u otopini pri čemu pH spomenutog pripravka je manji od 4,2 i veći od 2,0.
A medicament comprising an effective amount of at least one compound of formula (I) and/or a pharmacologically acceptable salt thereof according to one of claims 1 to 44, pharmaceutically tolerated excipients and carriers and, where appropriate, further additives and/or other active ingredients. 
Medikament, naznačen time što sadrži djelotvornu količinu najmanje jednog spoja formule (I) i/ili njegove farmakološki prihvatljive soli u skladu s bilo kojim od patentnih zahtjeva 1 do 44, farmaceutski podnošljive pomoćne tvari i podloge i, gdje je to prikladno, dodatne aditive i/ili druge aktivne sastojke.
is (substantially or entirely) free of amino acids or comprises one or more amino acids in a (collective) concentration of at most 0.1 mM; 
* ne sadrži aminokiseline ili sadrži jednu 1li više aminokiselina u (zajedničkoj) koncentraciji do najviše 0.1 mM: i
The expression “pharmaceutically acceptable salt, solvate or prodrug thereof” describes any pharmaceutically acceptable salt, eater, solvate or any other compound that, administered to a patient (directly or indirectly), provides a compound described herein. 
Izraz "farmaceutski prihvatljiva sol, ili njezin solvat" znači bilo koju farmaceutski prihvatljivu sol, ester, solvat ili bilo koji drugi spoj koji dat pacijentu (izravno ili posredno) daje ovdje opisan spoj.
The anti-FOLR1 antibody or anti-FOLR1 immunoconjugate for use of claim 1, wherein said reference sample is a positive reference sample or a negative reference sample, particularly wherein said reference sample comprises cells, cell pellets, or tissue. 
Protutijelo protiv FOLRI ili imunokonjugat protiv FOLRI, namijenjeni upotrebi u skladu s patentnim zahtjevom 1, naznačeni time što je navedeni referentni uzorak pozitivni referentni uzorak ili negativni referentni uzorak, osobito gdje navedeni referentni uzorak sadrži stanice, stanične pelete ili tkivo.
calculate the value of a function representative of the residual data items of the determined subset, 
- > izračunavanje vrijednosti funkcije koja predstavlja paritet zbroja preostalih stavki podataka navedenog određenog podskupa,